Posted by Michael Wonder on 06 Jan 2025
Star Therapeutics receives FDA fast track designation for VGA039 in von Willebrand disease
6 January 2025 - VGA039 is potentially the first subcutaneous therapy that addresses all types of von Willebrand disease and has a convenient dosing regimen.
Star Therapeutics today announced that the US FDA has granted fast track designation for VGA039 in von Willebrand disease.
